Enlivex Therapeutics Ltd.
ENLV
$1.09
$0.1414.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.21M | -1.87M | -3.45M | -5.18M | -2.60M |
| Total Depreciation and Amortization | 81.00K | 85.00K | 90.00K | 36.00K | 161.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 332.00K | 413.00K | -792.00K | 385.00K | 1.32M |
| Change in Net Operating Assets | -176.00K | 172.00K | -470.00K | 671.00K | -1.50M |
| Cash from Operations | -1.97M | -1.20M | -4.62M | -4.08M | -2.62M |
| Capital Expenditure | -21.00K | -7.00K | -32.00K | -35.00K | -9.00K |
| Sale of Property, Plant, and Equipment | 323.00K | 244.00K | 336.00K | 296.00K | 1.77M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.51M | 832.00K | 2.87M | 3.10M | -366.00K |
| Cash from Investing | 3.82M | 1.07M | 3.17M | 3.36M | 1.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 352.00K | -- | 203.00K | 1.91M | 250.00K |
| Repurchase of Common Stock | -- | -6.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 6.00K | -6.00K | -646.00K | -- |
| Cash from Financing | 352.00K | 0.00 | 197.00K | 1.26M | 250.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.20M | -129.00K | -1.25M | 535.00K | -970.00K |